Serum Auto-Antibodies in Neurological Diseases
Launched by UNIVERSITY OF CALIFORNIA, DAVIS · Jun 23, 2008
Trial Information
Current as of November 11, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This UC Davis study is looking for antibodies in the blood that may mistakenly attack parts of the nervous system. It’s an observational, forward-looking study, meaning researchers will follow participants over time to see how these antibodies change and whether they relate to how people’s diseases behave. At each visit, they will collect about 1 teaspoon (5 mL) of blood and a quick cheek swab, then test the blood for specific antibodies against certain nerve and muscle components. If a blood test comes back positive, researchers may ask for up to 8 more blood samples about every 3 months, for up to about 3 years.
Who can join: adults 18 or older who have multiple sclerosis, myasthenia gravis, or another autoimmune or inflammatory nervous system disease, and who can give informed consent. The study is conducted at UC Davis in Sacramento, California, and participants are enrolled by invitation, with a goal of about 120 people. The study does not involve treatment or giving a diagnosis, and results from the testing are not shared with participants. If you’re eligible and interested, talk with your doctor about whether you might be invited to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years or older
- • Diagnosis of multiple sclerosis, myasthenia gravis, or other autoimmune or inflammatory neurological disease
- Exclusion Criteria:
- • inability to give informed consent
About University Of California, Davis
The University of California, Davis (UC Davis) is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials and studies. With a strong focus on interdisciplinary collaboration, UC Davis leverages its extensive expertise in medical research, education, and patient care to drive breakthroughs in various fields, including medicine, public health, and agriculture. The university's clinical trial programs emphasize rigorous scientific methodology and ethical standards, aiming to translate research findings into impactful treatments and improved patient outcomes. Through its state-of-the-art facilities and a dedicated team of researchers and healthcare professionals, UC Davis is at the forefront of transforming healthcare practices and addressing critical health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sacramento, California, United States
Patients applied
Trial Officials
David Richman, MD
Principal Investigator
University of California, Davis
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials